Tauopathies with dementia and parkinsonism

Mary Ann Thenganatt MD (Dr. Thenganatt of the University of Pennsylvania has no relevant financial relationships to disclose.)
Joseph Jankovic MD, editor. (

Dr. Jankovic, Director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, received research and training funding from Allergan, F Hoffmann-La Roche, Medtronic Neuromodulation, Merz, Neurocrine  Biosciences, Nuvelution, Revance, and Teva and consulting/advisory board honorariums from Abide, Lundbeck, Retrophin, Parexel, Teva, and Allergan.

Originally released November 26, 2001; last updated March 26, 2019; expires March 26, 2022

This article includes discussion of tauopathies with dementia and parkinsonism. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.


The tauopathies are a group of neurodegenerative disorders that manifest as dementias and movement disorders. They have as a common pathological feature, the presence of intracellular accumulation of abnormal filaments of tau protein. The most common tauopathies, Alzheimer disease, progressive supranuclear palsy, corticobasal degeneration, Pick disease, and frontotemporal dementia with parkinsonism, present with either dementia, parkinsonism, or both. Clinical features may overlap, and accurate diagnosis may be challenging. In this article, the author reviews the clinical features, pathogenesis, diagnostic work-up, and potential therapies for this group of disorders.

Key points


• Tauopathies with dementia and parkinsonism represent a group of disorders with shared underlying pathology of intracellular accumulation of tau protein.


• These pathologically defined disorders can manifest with a broad range of phenotypes, in addition to the classically associated syndromes.


• Classical clinical features can help distinguish these disorders, but there is often marked overlap of clinical features.


• There are no confirmatory diagnostic tests in vivo, but ancillary testing such as imaging may be helpful.


• The diagnostic gold standard for these disorders remains postmortem pathologic confirmation.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology